左卡尼汀对新生儿血清CK-MB水平的影响及其临床意义

Effect and Clinical Significance of Levocarnitine on Neonatal Serum CK-MB Level

目的探讨左卡尼汀对新生儿血清CK-MB水平的影响及其临床意义。方法选取我院2012年1月~2014年1月血清CK-MB异常新生儿80例,数字抽取分为大剂量左卡尼汀组、小剂量左卡尼汀组,对照组为血清CK-MB正常组,分析各组治疗效果。结果各组7 d内血清CK-MB稳定下降率差异有统计学意义（P〈0.05）：各组治愈率差异无统计学意义（P〉0.05）。出生后第3天血清CK-MB水平均降低（P〈0.05）;出生后第7d血清CK-MB较第3天下降百分比差异有统计学意义（P〈0.05）。结论左卡尼汀可以降低新生儿异常血清CK-MB水平。

Objective To study the Levocarnitine effects on neonatal serum CK- MB level and its clinical significance. Methods From January 2012 to January 2012, 80 cases of newborn, abnormal serum CK- MB digital extraction into large doses of Levocarnitine group and small doses of Levocarnitine group, normal group, control group of serum CK- MB analysis between groups therapeutic effect. Results Each group within 7 d serum CK- MB in steady decline rate difference was statistically significant（P〈0.05）, there was no statistically significant difference between groups cure rate（P〉0.05）. 3 day after the birth of the level of serum CK- MB was lower（P〈0.05）; After the birth of 7 d serum CK- MB is 3 days down percentage difference was statistically significant（P〈0.05）. Conclusion Levocarnitine can reduce neonatal abnormal level of serum CK- MB, and high clinical value.